Kiniksa Pharmaceuticals Valuation
| KNSA Stock | USD 23.36 0.45 1.89% |
At this time, the firm appears to be fairly valued. Kiniksa Pharmaceuticals secures a last-minute Real Value of $23.95 per share. The latest price of the firm is $23.36. Our model forecasts the value of Kiniksa Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 1.46 B, return on equity of -0.0985, and Profit Margin of (0.10) % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Kiniksa Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Kiniksa Pharmaceuticals is based on 3 months time horizon. Increasing Kiniksa Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Kiniksa Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Kiniksa Stock. However, Kiniksa Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 23.36 | Real 23.95 | Hype 23.36 | Naive 23.76 |
The real value of Kiniksa Stock, also known as its intrinsic value, is the underlying worth of Kiniksa Pharmaceuticals Company, which is reflected in its stock price. It is based on Kiniksa Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Kiniksa Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Kiniksa Pharmaceuticals helps investors to forecast how Kiniksa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Kiniksa Pharmaceuticals more accurately as focusing exclusively on Kiniksa Pharmaceuticals' fundamentals will not take into account other important factors: Kiniksa Pharmaceuticals Total Value Analysis
Kiniksa Pharmaceuticals is now projected to have valuation of 1.46 B with market capitalization of 1.7 B, debt of 9.86 M, and cash on hands of 138.21 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Kiniksa Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.46 B | 1.7 B | 9.86 M | 138.21 M |
Kiniksa Pharmaceuticals Investor Information
About 90.0% of the company shares are owned by institutional investors. The book value of Kiniksa Pharmaceuticals was now reported as 6.05. The company has Price/Earnings To Growth (PEG) ratio of 0.25. Kiniksa Pharmaceuticals recorded a loss per share of 0.6. The entity had not issued any dividends in recent years. The firm had 1:1 split on the 28th of June 2024. Based on the key indicators related to Kiniksa Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Kiniksa Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Kiniksa Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Kiniksa Pharmaceuticals has an asset utilization ratio of 72.9 percent. This suggests that the Company is making $0.73 for each dollar of assets. An increasing asset utilization means that Kiniksa Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Kiniksa Pharmaceuticals Ownership Allocation
Kiniksa Pharmaceuticals maintains a total of 42.01 Million outstanding shares. The majority of Kiniksa Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kiniksa Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kiniksa Pharmaceuticals. Please pay attention to any change in the institutional holdings of Kiniksa Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Kiniksa Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 423.24 M. Net Loss for the year was (43.19 M) with profit before overhead, payroll, taxes, and interest of 234.02 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Kiniksa Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Kiniksa Pharmaceuticals and how it compares across the competition.
About Kiniksa Pharmaceuticals Valuation
The stock valuation mechanism determines Kiniksa Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Kiniksa Pharmaceuticals. We calculate exposure to Kiniksa Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Kiniksa Pharmaceuticals's related companies.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda. Kiniksa Pharmaceuticals is traded on NASDAQ Exchange in the United States.
Kiniksa Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 71.4 M | |
| Quarterly Earnings Growth Y O Y | 5.5 |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |